Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | MAPT | P10636 | 2/20 | 0.36 |
| ▸ | KCNH2 | Q12809 | 1/20 | 0.36 |
| ▸ | GAA | P10253 | 1/20 | 0.35 |
| ▸ | ALDH1A1 | P00352 | 1/20 | 0.35 |
| ▸ | MEN1 | O00255 | 1/20 | 0.35 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.35 |
| ▸ | EPHX2 | P34913 | 1/20 | 0.35 |
| ▸ | CYP3A4 | P08684 | 1/20 | 0.35 |
| ▸ | CYP2D6 | P10635 | 1/20 | 0.35 |
| ▸ | CYP2C9 | P11712 | 1/20 | 0.35 |
| ▸ | CYP2C19 | P33261 | 1/20 | 0.35 |
| ▸ | PPM1B | O75688 | 1/20 | 0.34 |
| ▸ | PTPN1 | P18031 | 1/20 | 0.34 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL24136969 | 0.81 | CYP3A4 (0.36) | MAPTCYP3A4 | |
| SCHEMBL10217221 | 0.81 | MAPT (0.36) | MAPTKCNH2ALDH1A1MEN1KMT2A | |
| SCHEMBL9082047 | 0.79 | ALDH1A1 (0.37) | MAPTKCNH2ALDH1A1MEN1KMT2A | |
| SCHEMBL28153158 | 0.78 | CYP3A4 (0.44) | MAPTKCNH2ALDH1A1CYP3A4 | |
| SCHEMBL28153157 | 0.78 | CYP3A4 (0.44) | MAPTKCNH2ALDH1A1CYP3A4 | |
| SCHEMBL2097353 | 0.74 | PREP (0.61) | MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL15934593 | 0.74 | PREP (0.61) | MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL17862217 | 0.74 | PREP (0.61) | MAPTALDH1A1MEN1KMT2A | |
| SCHEMBL21966212 | 0.74 | PREP (0.40) | MAPTKCNH2ALDH1A1MEN1KMT2A | |
| SCHEMBL6621402 | 0.74 | PREP (0.61) | MAPTALDH1A1MEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20080214529-A1 | SATURATED FUSED [1,2-b]PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. | 2008-09-04 | — | — | US | disclosed |
| US-20080214529-A1 | SATURATED FUSED [1,2-b]PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. | 2008-09-04 | — | — | US | disclosed |
| US-20080214529-A1 | SATURATED FUSED [1,2-b]PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. | 2008-09-04 | — | — | US | disclosed |
| WO-2008073987-A1 | SATURATED FUSED [1,2-B] PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
| WO-2008073987-A1 | SATURATED FUSED [1,2-B] PYRIDAZINONE COMPOUNDS | ANADYS PHARMACEUTICALS, INC. (US) | 2008-06-19 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (1 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20080214529-A1 | SATURATED FUSED [1,2-b]PYRIDAZINONE COMPOUNDS | HAVCR2, ZC3HAV1, NR1H4 | MAPT 2107/4885KCNH2 1543/4885GAA 2633/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.